Inclusion Body Myositis Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 – DelveInsight | Key Companies – Orphazyme, Alzehon, Kv1.3 Therapeutics, and Others

May 09 20:32 2022
Inclusion Body Myositis Market to Grow at a Substantial Growth Rate During the Forecast Period 2032 -  DelveInsight | Key Companies -  Orphazyme, Alzehon, Kv1.3 Therapeutics, and Others
Delveinsight Business Research LLP
DelveInsight’s “Inclusion Body Myositis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Inclusion Body Myositis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Inclusion Body Myositis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Inclusion Body Myositis Market

Inclusion Body Myositis: An Overview

Inclusion body myositis (IBM) is a slowly progressive skeletal muscle disease with unique clinical and pathological features (including finger flexor and quadriceps weakness and the presence of infiltrating cytotoxic T cells in muscle). IBM is classified along with polymyositis, dermatomyositis, and autoimmune necrotizing myopathy as one of the idiopathic inflammatory myopathies (a group of disorders characterized by inflammation of the skeletal muscle).

Novel treatment options, better disease understanding along with increasing awareness, are expected to drive the growth of the IBM therapeutic market in the coming years.

Inclusion Body Myositis Market Key Facts

  • A study titled “Epidemiology of sporadic inclusion body myositis”, in 2016 specified that the population prevalence of sporadic IBM in Northern Europe to 3.3/100 000, which is higher than in previous studies.

  • A Study titled “Increase in the number of sporadic inclusion body myositis (sIBM) in Japan”, 2012 stated that the prevalence was less than 10 per million in 2003, but rose towards 2012.

Inclusion Body Myositis Market

As per DelveInsight, the Inclusion Body Myositis market size is expected to increase during the forecast period owing to the high prevalence of the disorder and the growing geriatric population in the 7MM. The expected launch of therapies will also fuel the growth of the market growth.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Inclusion Body Myositis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Inclusion Body Myositis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), competition with other therapies, brand value, and their impact on the market.

Inclusion Body Myositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Inclusion Body Myositis Epidemiology Segmentation –

  • Age-Specific Prevalent Cases 

  • Prevalent Cases 

  • Symptom-Specific Prevalent Cases

  • Symptom-Specific Prevalent Cases 

  • Diagnosed and Treatable Cases

Inclusion Body Myositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Inclusion Body Myositis market or expected to get launched during the study period. The analysis covers the Inclusion Body Myositis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Inclusion Body Myositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report – https://www.delveinsight.com/sample-request/inclusion-body-myositis-market

Inclusion Body Myositis Therapeutics Analysis

The Inclusion Body Myositis pipeline is not robust despite the tremendous progress that has been made in the clinical and pathogenic understanding of IBM over the past decade. Increasing prevalence and rising demand for advanced therapeutics for specific and effective treatment of IBM are expected to fuel the market growth during the forecast period.

Some of the key companies in the Inclusion Body Myositis Market include:

  • Orphazyme

  • Alzehon

  • Kv1.3 Therapeutics

And many more. 

Inclusion Body Myositis Therapies covered in the report include:

  • Arimoclomol

  • ALZ-507

  • Dalazatide

And many others.

Get More Detailed Insights Into the Emerging Therapies & Key Companies – 
https://www.delveinsight.com/sample-request/inclusion-body-myositis-market

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Inclusion Body Myositis Competitive Intelligence Analysis

4. Inclusion Body Myositis Market Overview at a Glance

5. Inclusion Body Myositis Disease Background and Overview

6. Inclusion Body Myositis Patient Journey

7. Inclusion Body Myositis Epidemiology and Patient Population

8. Inclusion Body Myositis Treatment Algorithm, Current Treatment, and Medical Practices

9. Inclusion Body Myositis Unmet Needs

10. Key Endpoints of Inclusion Body Myositis Treatment

11. Inclusion Body Myositis Marketed Products

12. Inclusion Body Myositis Emerging Therapies

13. Inclusion Body Myositis Seven Major Market Analysis

14. Attribute Analysis

15. Inclusion Body Myositis Market Outlook (7 major markets)

16. Inclusion Body Myositis Access and Reimbursement Overview

17. KOL Views on the Inclusion Body Myositis Market.

18. Inclusion Body Myositis Market Drivers

19. Inclusion Body Myositis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report – https://www.delveinsight.com/sample-request/inclusion-body-myositis-market

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Other Latest Reports By DelveInsight

Osteochondrodysplasia Market

DelveInsight’s “Osteochondrodysplasia Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Osteochondrodysplasia Market size, share, and trends analysis in the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Shruti Thakur
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

  Categories: